2018
DOI: 10.1210/jc.2018-01589
|View full text |Cite
|
Sign up to set email alerts
|

Recombinant Thyrotropin vs Levothyroxine Withdrawal in 131I Therapy of N1 Thyroid Cancer: A Large Matched Cohort Study (ThyrNod)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
16
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 13 publications
(17 citation statements)
references
References 29 publications
1
16
0
Order By: Relevance
“…Although there is a trend toward higher ablation rates with higher activities in patients with large thyroid remnants as observed in the past, similar rates of successful remnant ablation have been reported using activities ranging from 1110 to 3700 MBq of I-131 ( 47 , 48 , 49 , 50 ). A randomized study using preparation with rhTSH showed that ablation rates were comparable with 1850 MBq or 3700 MBq ( 47 ).…”
Section: Activity Of I-131 To Be Employed For Post-surgical Thyroid R...supporting
confidence: 72%
See 1 more Smart Citation
“…Although there is a trend toward higher ablation rates with higher activities in patients with large thyroid remnants as observed in the past, similar rates of successful remnant ablation have been reported using activities ranging from 1110 to 3700 MBq of I-131 ( 47 , 48 , 49 , 50 ). A randomized study using preparation with rhTSH showed that ablation rates were comparable with 1850 MBq or 3700 MBq ( 47 ).…”
Section: Activity Of I-131 To Be Employed For Post-surgical Thyroid R...supporting
confidence: 72%
“…The remnant ablation rate was similar in all groups irrespective of the TSH stimulation method used, and the authors concluded that recombinant human thyrotropin is equally effective for preparation for remnant ablation in low-risk patients. In addition, shortterm recurrence rates have been found to be similar in patients prepared with thyroid hormone withdrawal or rhTSH, both in low (11,48) and intermediate-risk patients (49,50). Furthermore the preparation with rhTSH is associated with an unimpaired quality of life (46,51), and reduces both the whole body radiation absorbed dose (38,39) and duration of hospitalization (6,41,43,52).…”
Section: Preparation For Rai Administrationmentioning
confidence: 96%
“…Also, in iodine-deficient countries, those tumors are often an incidental finding after surgery for goiter. Given the fairly high percentage of lymph node metastases even in pT1a (12-50%, according to Perros et al [10]), radioiodine treatment in low-intermediate risk tumors in many cases will have an adjuvant approach, besides ablative aspects [11].…”
Section: Low-risk Dtcmentioning
confidence: 99%
“…In patients with a higher risk of recurrence, where RAI is being used as adjuvant therapy, rhTSH may be 'considered as an alternative to THW'. At our institution, as is similar at many institutions with large thyroid tumor programs, we almost exclusively use rhTSH preparation for patients being treated as adjuvant therapy and remnant ablation, based on multiple short-term follow-up studies (Mallick et al 2012b, Schlumberger et al 2012, Pak et al 2014, Tu et al 2014, Leenhardt et al 2019. Patients who are at high risk for recurrence need individualized decision-making about using rhTSH or THW since the evidence is more limited in this subgroup (Tala et al 2011, Klubo-Gwiezdzinska et al 2012, Iizuka et al 2020.…”
Section: Logistical Considerationsmentioning
confidence: 99%